DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

02591 INNOGEN-B

Trading Add to Porfolio
Index Constituent : None
Major Shareholders Wang Qinghua (27.22%)
Korea Investment Holdings Co., Ltd. (9.14%)
Hong Kong Invengen Pharmaceutical Technology Co., Limited (5.97%)
Cowin China Growth Fund II, L.P. (5.81%)
Temasek Holdings (Private) Limited (5.55%)		 Sector Health Care & Biotechnology
Web Site http://www.innogenpharm.com Tel N/A
Email info@innogenpharm.com Fax N/A
Related Equities N/A
Principal Activities Principally engaged in the research, development and commercialisation of pharmaceutical products.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top